$ESPR Bio – Future catalyst with neutral view
ESPERION THERAPEUTICS, INC. NASDAQ:ESPR
Future Catalyst:
October 2018 10/31/2018
Phase 3 data due October, 2018.
Market cap: 1.2B. Float: 24.25M
Company Notes – Negative income, 57 employees, 0 debt, 14% Inst owned, mixed analysis opinion.
50/50 split bulls/bears- I’m suspecting this will continue to bounce a little of its multiple bottom and have some natural longs take this stock up into the catalyst BUT with their history in poor earnings results I expect this to sell off back to the recent support and depending on the results of P3 could be looked at negatively buy investors.